MEDTECH, BIOTECH & PHARMA | 2023 THE INDUSTRY JOURNAL OF HAMBURG & SCHLESWIG-HOLSTEIN INNOVATIVE HIV THERAPY Provirex‘ genome editing approach is heading to the clinic THE BRAINSTORMER Christian Gerloff‘s plans for the University Medical Center Hamburg- Eppendorf (UKE) ECOSYSTEM BUILDERS How artificial intelligence applications and robotics are transforming the health industry in the North of Germany

EDITORIAL | LSN MAGAZINE 3 23 Dear readers, I am delighted that you are now holding the hot-off-the-press LSN Magazine 2023 in your hands. It is my first LSN Magazine since I started as Managing Director of Life Science Nord in June 2022. I am also pleased that I can give you a brief overview of the once again great topics and stories in this issue. Although AI in medicine is highly innovative, it’s already an established field of research and development in the LSN region. However, it is not only the results of individual players that are remark- able, but rather the entire AI ecosystem that has emerged with research, industry and politics all working in concert. The interview with Dirk Schrödter, Head of the State Chancellery of Schleswig-Holstein and Minister of Digitalization, shows how AI in healthcare can be implemented as part of a holistic strategy incorporating politics, business, and science. The North is also in an excellent position on the research side. For instance, Stefan Fischer, Vice-President Transfer and Digitization of Lübeck Uni- versity, impressively reports on how this succeeds, using the example of the KI-Med ecosystem in Lübeck. Fascinating examples express the wide range of AI applications: from high-speed protein puzzling on the DESY campus, to the use of AI-supported ana- lytics in clinical pathology and in surgical robotics at Fraunhofer IMTE and UKSH, to additive manufacturing processes. In the North, AI has enormous potential to shape healthcare with the innovative power of the LSN cluster players. AI-based solutions, as one of the building blocks of an overall digitalization strategy, are providing the answers to many questions of the future. This issue naturally has much more to offer: Nanotechnology, high-tech devices for emergency care, bioanalytics, stem cell research, exciting start-ups, a portrait of the new UKE Managing Director... and more! On behalf of the entire LSN team, I hope they enjoy browsing through the magazine! Sincerely yours, JOINING FORCES FOR SUCCESS: WE WANT YOUR INPUT! Please send information and views to: magazin@lifesciencenord.de PROJECT MANAGEMENT: Dr Philipp Graf EDITORS OF THIS EDITION: Dr Philipp Graf (pg), Dr Doreen Penso Dolfin (dpd), Margarita Milidakis (mm) PROOFREADING: Andrea Murphy, Mark Chorlton ART DIRECTION: Michaela Reblin PRODUCTION: Martina Willnow PICTURES: Cover, p.8, 20–21 Florian Sänger; p.3 LSN; p.6 European XFEL, p.7 Daniel Reinhardt; hammeskrause architekten bda; p.9 Agnieszka Obarska-Kosinska; p.10, 11 Mindpeak; p.12 Staatskanzlei S-H; p.14 Stefan Fischer p.15 lienchen020_2/stock.adobe.com; p.16 Model:Eric Aderhold; p.18 Rainer Jensen/Fraunhofer IMTE; Jürgen Haaks /CAU; Philipp Graf below p.19 Fraunhofer IMTE, Kiel University, UKSH; p.22 Weinmann Emergency; p.24 Catrin-Anja Eichinger; p.25 Niklas Beschorner/Provirex, Illustration by SCIstyle for LIV; p.26 BioAgilytix Europe; p.27 Evotec, Heine Architekten Partnerschaft; p.28 Dr. Brill, p.29 Dr. Brill, Dr. Weigert, LSN; p.30–31 Fraunhofer IMTE/Thomas Friedrich; p.32 UKE; p. 33 top and middle Fraunhofer IAPT, below University of Lübeck; p.34–35 Fraunhofer IAP, Neus Feliu Torres p.36–37 Philipp Graf; p.38 mobOx; p. 39 Wilm Ihlenfeld/ bismillah_bd/stock.adobe. com; p.40 Dilok/stock.adobe.com; p.41 NDABCREATIVITY/ stock.adobe.com; p.42 LSN/Inga Sommer, p.44 DESY PRINT: Schipplick + Winkler Printmedien GmbH LSN Magazine for Medtech, Biotech und Pharma is published once a year. gEmEiNsAm mEHr ErrEiCHEN: iHr iNpuT isT gEfrAgT! Informationen und Meinungen DR JÜRGEN WALKENHORST bitte an: MANAGING DIRECTOR anja.rasch@norgenta.de LIFE SCIENCE NORD MANAGEMENT GMBH Sie möchten das Magazin kostenlos regelmäßig beziehen? Abo-Bestellung: info@norgenta.de imprEssum HERAUSGEBER IMPRINT PUBLISHER LIFE SCIENCE NORD Life Science Nord Management GmbH Geschäftsführung: Dr. Hinrich Habeck Falkenried 88, 20251 Hamburg Life Science Nord Management GmbH Tel.: +49.40.471 96 400, Managing Director: Dr Jürgen Walkenhorst Falkenried 88, 20251 Hamburg Fax: +49.40.471 96 444 Tel.: +49.40.593 62 61-0 info@lifesciencenord.de info@lifesciencenord.de www.lifesciencenord.de www.lifesciencenord.de UNTERSTüTZT VON: SUPPORTED BY: EDITORIAL BOARD REDAKTION Jan Phillip Denkers (responsible under press law) Life Science Nord Management GmbH Dr. Anja Rasch (V.i.S.d.P.), REALIZATION BIOCOM AG, Berlin Norgenta Norddeutsche Life Science Agentur GmbH REALISATION nicole suchier_science communication hamburg, www.nicolesuchier.de Ein Wechsel steht auch an der Christian- Al brechts-Universität (CAU) Kiel an. Prof. Lutz Kipp wird am 1. Juni sein Amt als Prä- sident der Hochschule antreten. Der Physiker Kipp hat an der CAU studiert, promoviert und sich dort auch habilitiert. Er ist unter an- derem Mitglied des Komitees für Forschung mit Synchrotronstrahlung sowie Vizespre- cher des Kieler Sonderforschungsbereichs „Magnetoelektrische Verbundwerkstoffe – biomag netische Schnittstellen der Zukunft“. zeichnet. Die erste Frau an der Spitze der Fachhochschule Lübeck wird ab dem 1. Au- gust Dr. Mu riel Kim Helbig sein. Sie hat Psy- chologie an der Universität Potsdam studiert. Nach der Promotion an der Friedrich-Schil- ler-Universität Jena (FSU) war sie an der FSU überwiegend im Wissenschaftsmanage- ment tätig. Seit 2009 befasst sich Helbig als Dezernentin für internationale Beziehungen an der Bauhaus-Universität Weimar mit Aspekten der Internationalisierung der Uni- versität. Mit ihr ist erstmals eine externe

16 EDITORIAL | LSN MAGAZINE 5 30 28 36 SCIENCE & TRANSLATION 28–35 BOOTCAMP EFFECTIVE AGAINST OUTBREAK STRAINS A HIHeal consortium project has evaluated the efficacy of disinfectants with regard to antibiotic-resistant outbreak strains. 3D PRINTING MEETS MEDICINE Researchers in the North combine AI with additive manufacturing technologies to take precision medicine to the next level. 28–29 TILL BÖHME: CO-FOUNDER OF MOBOX Interview with the Managing Director of mobOx. STARTING UP IN THE NORTH A map on incubators, advice & financing for Life Science companies 30–33 CAREER 38–39 38 39 40–41 TUMOR BIOMARKER TRACKERS A Fraunhofer team has developed a sensitive method based on nanoparticles to detect biomarkers to improve liquid biopsy. 34–35 REACHING TOP SCORES IN EMPLOYER AWARDS Last year, three member companies of the Life Science Nord Cluster were recognized for their efforts in employee support and for showing responsibility as regional employers. PROFILE THE BRAINSTORMER Christian Gerloff is the new Medical Director of the University Medical Center Hamburg-Eppendorf (UKE). 36–37 36–37 PHARMA INNOVATION MADE IN GERMANY Allergopharma has specialized in the development, production and commercialization of medical drugs for the diagnosis and treatment of allergic diseases. GET IN TOUCH LIFE SCIENCE NORD – WHO WE ARE 40 41 42 42

SHORT NOTES | LSN MAGAZINE 7 MARINE BIOPOLYMERS FOR MEDICINE BlueBioPol — a project which is part of the regional research alliance Blue- HealthTech aims to develop medical materials made of marine biopolymers. Collagen from jellyfish or alginate from macroalgae are generally considered biocompatible and biodegradable. As building blocks for carrier materials such as hydrogels, they could enable the treatment of tissue damage caused by chronic disease. The project bundles maritime and medical competencies of the Kiel region and has received around 800,000 Euros in funding from the Fed- eral Ministry of Education and Research (BMBF). KATHARINA FEGEBANK Second Mayor of the Free and Hanseatic City of Hamburg and Senator for Science, Research, Equality and Districts CROSS-BORDER COOPERATION… “… projects such as HALRIC mean we can continue our close transnational cooperation between Hamburg Metropolitan region, Greater Copenhagen and Skåne. This will help us to further position the region as a world-leading life science hub.” è see also page 20–21 NEW HOME è The Fraunhofer Institute for Additive Manu- facturing Technologies IAPT is being expanded with a highly specialized building at its site in Hamburg-Bergedorf. The building is being erected in a sustainable design with a modular wood construction. è see also page 30–33

AI IN MEDICINE SPECIAL | LSN MAGAZINE 9 lar modelling. “Before, we didn’t know anything about the structure of many of the proteins within the NPC. You cannot assemble a puzzle when you don’t know what the pieces look like. But Alpha- Fold2, combined with other approaches, enabled us to predict those shapes.” The resulting model, published in top journal “Science”, was so complete and detailed that it enabled the researchers to create time-resolved molecular simulations that shed more light on how the NPC works. for us.” “AlphaFold2 was a breakthrough moment DR AGNIESZKA OBARSKA-KOSINSKA EMBL HAMBURG AND MPI OF BIOPHYSICS and EMBL’s European Bioinformatics Institute (EMBL-EBI) have partnered to create a database for making the predictions freely available to the scientific community. The database now includes over 200 million protein models. “This means we have models for almost every catalogued protein known to science,” Ko- sinski says. After having cracked the struc- tural code of the NPC, his group at EMBL Hamburg is now focusing on even more difficult molecular puzzles in infection biology. “We are now using AlphaFold2 in combination with our own software to model the structures of viruses such as in- fluenza and Lassa to map their interactions with human proteins. We have also just started a bigger project on the malaria parasite funded by the CSSB.” AI-based structural biology hotspot Jan Kosinski sees three aspects that have made AlphaFold2 a game changer for his and his team’s way of doing protein science. “It speeds up our work – we get a good impression of what the protein we are work- ing on looks like within minutes instead of months or years,” he says. “It makes our work easier, and finally, AlphaFold2 makes our work more fun – many technical and tedious steps are now automated so we can focus more on our biological questions!” Since its sensational debut, AlphaFold2 has been developed further. Kosinski points out that scientists now have a better understand- ing of where the software works best, and in which aspects it cannot replace experimental methods. For example, while Alpha- Fold2 gives an idea about the structure of a protein, X-ray and high-resolution cryo-electron microscopy (cryo-EM) methods still usually give the more precise structures needed for under- standing enzymatic reactions or designing drugs. DeepMind Jan Kosinski is convinced that Hamburg has the potential to de- velop into a hotspot for AI-based structural biology. At EMBL Ham- burg and CSSB, there are already a number of AI-based projects in structural biology. There is also a growing AI community at the DESY campus including researchers from other disciplines such as physics or instrumentation. “I think our potential to attract AI experts or students lies in tackling important problems in funda- mental biology and questions relevant to human health.” pg

AI AND CANCER Other Hamburg-based companies in the Life Science Nord cluster using AI-based approaches for precision oncology in- clude Evotec, FUSE-AI and Indivumed. and the platform behind it,” Faber says. Developing the platform itself took about 2.5 years. The first product recognizes and clas- sifies breast cancer cells in tissue samples taken in a fraction of a second. The software received its CE-IVD mark in May 2021. “This made us the first company in Germany with such an ap- proval in clinical routine diagnostics in pathology,” says Faber. Working hard to develop a platform is now paying off for the product portfolio and the development pipeline. “We are now able to release algorithms much faster than before,” Faber says. He reckons that one of Mindpeak’s greatest assets is the algo- rithm analyzing the biomarker PD-L1, which is of major impor- tance in the dynamic field of immuno-oncology. Faber says the IVDR and the limited number of Notified Bodies are major bar- riers now. “That is why we are likely to put only two products on the market in 2023,” he adds. Explainable AI earning the trust of users The success of AI-based approaches relies on the quality and quantity of the data used to train the algorithm. Having access to tissue slides from partner laboratories is an important asset for Mindpeak in this respect. And there are also a limited num- ber of customers which allow the start-up to train with their data. A network of over 30 pathologists annotate data based on rigid guidelines and create ground truth data to train the AI. All Mindpeak products “explain” how they made a decision, al- lowing pathologists to understand and trust it. “We always show what the neural network detected and how it came up with the score.” Faber points out that explainability is absolutely necessary to get acceptance for AI-based solutions on the market. Another special feature is what the Mindpeak team calls a zero-click so- lution. The system pre-processes all the cells on the whole slide AI IN MEDICINE SPECIAL | LSN MAGAZINE 11 with two AIs and the pathologists are presented with all the re- sults when they open the case. “It gives you a good overview and saves a couple of seconds, which doesn’t seem like much, but if you know how pathologists work, this is extremely important to the workflow.” For example, Mindpeak’s customer Unilabs, one of the largest European diagnostics providers, introduced its AI solution to the clinical routine to speed up breast cancer diagnosis and make it more accurate. It recently reported a 90% reduction in diagnosis time with the Mindpeak solution. “They say they are ten times faster and will now make it standard in Sweden.” The start-up is funded by the Innovationsstarter Funds Ham- burg (IFH), with support from APEX Ventures, Nina Capital, Motu Ventures, and prominent angel investors. Mindpeak, with a team of 25 employees, has raised 9 million euros so far. “We want to grow our team in 2023,” says Faber. Since more than two thirds of revenue come from the business in the United States, Mindpeak is going to open a Sales Office there soon. When it comes to recruiting, Felix Faber says it’s helpful that data scientists and machine learning experts show interest in the healthcare market. “With our purpose-driven approach, we pg are able to attract talent.” More information: www.mindpeak.ai FELIX FABER is Co-Founder and CEO of Mindpeak (left). Dr Tobias Lang is Co- Founder and CTO of the Hamburg-based start-up.

„The strong Life Science Nord Cluster is the DNA, or the breeding ground, of the AI-Med ecosystem.” Minister Schrödter, you recently gave your 2019 AI strategy for Schleswig-Holstein an update. Why? DIRK SCHRÖDTER With its own AI strategy, in 2019 the state of Schleswig-Holstein became a pioneer in Germany. We are receiving a great deal of attention, both nationally and internationally, for how we implement this regionally and how we have developed a clear profile. But we all know: The field is developing at breakneck speed, and we are keep- ing pace in Schleswig-Holstein. With strategy version 2.0, we are placing even greater emphasis on the applications of AI in areas where the North has clear competitive advantages. In addition to the healthcare industry, these core areas in- clude the field of renewable energies and the blue economy. This should result in growth, value creation and jobs for our state. In total, we are providing more than 45 million euros in implementing the strategy, with further EU funding on top. Why is the North predestined to develop an AI ecosys- tem in the healthcare industry? SCHRÖDTER In Schleswig-Hol- stein, we already have close links between business, science and gov- ernment. There is a very active and creative AI scene and the paths to government are short. We have also created good conditions in the compe- tition for attracting the best minds to the region. We are currently filling 12 new AI professorships at universities – the North has devel- oped appeal. The Life Science Nord cluster is an extremely important partner. This strong cluster is something like the DNA or the breeding ground on which we can build an AI- Med ecosystem. In the AI medtech ecosystem, the Lübeck area plays a prominent role as a location... SCHRÖDTER In the Lübeck area, a truly unique network has emerged for the application of AI technologies in medi- cal technology and the healthcare industry. It is shining so brightly, that it is already having an impact far beyond the state’s borders. Here, we have initiated more intensive coop- eration between research institutions and the private sector, creating very important added value for the state. We need ecosystems of this kind with many players who cross-fertil- ize each other and create competitive advantages for our re- gion. We are supporting this with 4 million euros. What role does the public-private consortium KI-SIGS play here? SCHRÖDTER The KI-SIGS consortium, funded by the German Federal Ministry of Economic Affairs and Cli- AI IN MEDICINE SPECIAL | LSN MAGAZINE 13 mate Action, brings together the most important players from medicine, the healthcare industry and AI in north- ern Germany and embodies the goals of our AI strategy in the best possible way: High-tech, networked, and agile – and close to clinical application. Over the past few years, a very successful network has been built up, despite the tough COVID years – that’s really impressive. We want to keep this momentum going and spread the reach of the network even more broadly in the future. This includes bringing on board other German states such as Mecklen- burg-Vorpommern. How do you plan to embed the AI-Med ecosystem into the GAIA-X European data infrastructure? SCHRÖDTER The GAIA-X-Med initiative is seeing the cre- ation of a networked data platform to process medical data securely, in a standardized way, and efficiently. We are also investing 4 million euros in this project. GAIA-X-Med is a very important building block in our regional AI-Med ecosystem. Linking this with GAIA-X tech- nologies is forward-looking, as it simultaneously allows us to sup- port the European Cloud Initiative and participate in its further de- velopment, while at the same time also creating digital sovereignty. You are funding several projects related to AI-assisted robotic systems in surgery (see p.16-19 in this issue). What potential do you see here? SCHRÖDTER AI-assisted robotic systems in surgery open up a huge field of application. It’s not just about improv- ing healthcare. We can achieve technological leaps that enable us to become a technology exporter. In surgical ro- botics, we are entering an innovation gap that can bring us additional value creation. This attracts skilled workers, cre- ates new jobs, and has many other self-reinforcing effects. Concerning data availability: How do you intend to achieve improvements here? SCHRÖDTER The question of data availability is absolute- ly central to the implementation of our AI strategy. We can no longer let health data lie unused in data silos. In recent months, we have developed the cornerstones of a state data strategy through which we want to decisively improve data provision and data availability. It is set to be adopted at the end of 2023. Data provision will become the norm here. In par- allel, we are also working on the technical requirements for making data available to SMEs in a machine-readable form. We need a culture of data sharing and data use in Germany, pg and we want to become a digital showcase region.

AI IN MEDICINE SPECIAL | LSN MAGAZINE 15 LIROS Linking AI and robotics KI-SIGS Development platforms AI reference applications KI-Med Identification, specification of medical applications GAIA-X-Med Exchange standards Data interfaces AnoMed Anonymization processes and services KI-Med ecosystem KI-Transfer Hub Awareness/ motivation integration SME MCEA Hybrid expert- system architecture KI-LAB Computer power & engineering support KI-Service- zentrum Methods, tools, service for AI development projects DFKI AI research & application developments An overview of projects relevant for building up the AI-Med (KI-Med) ecosystem in the North A perspective for KI-SIGS As a cross-state consortium, KI-SIGS involves partners from the German states of Bremen, Hamburg and Schleswig-Holstein. “Based on the AI-Med ecosystem, project participants can ac- cess nine application projects and a four-part platform. Through input and feedback from the partners into these components of the platform, the know-how grows and thus the ecosystem should be further strengthened,” says Fischer. “The cross-border collaboration has worked wonderfully so far,” he adds. KI-SIGS will continue to be financed by federal funds until the end of 2023. The collaboration of current and future participants via the KI-SIGS platform components with regard to AI research and the resulting application and product developments is to be consolidated. The KI-SIGS team headed up by Spokesman Stefan Fischer and Project Manager Martin Leucker, Head of _> UniTrans- ferKlinik in Lübeck, is already looking to secure for follow-up funding. The partners have developed an application concept for an KI-Med Servicezentrum, in which Mecklenburg-Vor- pommern would also like to participate as a new federal state partner. The aim of the KI-Med Servicezentrum is to develop and provide standardized methods and tools as well as pro- fessional services for innovative AI development projects. The state-funded project GAIA-X-MED creates a secure and networked data and service infrastructure using Eu- ropean defined interface and architecture standards as a basis for further scalable AI-Med applications. The techni- cal exchange standards are tested and applied in six real use cases with the participation of companies and the UKSH. Speaking of data availability, the university and its AI-Med eco- system partners have just secured a new 10-million-euro project, AnoMed, from the federal governmen. It aims to develop data anonymization techniques for medical data. Success factors One factor that Fischer reckons is essential for the ecosystem to thrive is the strong commitment of health care providers to collaborative projects. He also sees a need for cross-clinic inte- gration of user experience as well as data availability to achieve broad application scenarios of medical AI applications in diverse technical and process-related application environments. And there is a need for a clear perspective for the commercialization of scalable product developments. Finally, the medical, techni- cal, regulatory, and economic feasibility of medical AI product developments must be clarified early. “Here in Lübeck and be- pg yond, we have created good conditions for this.”

AI IN MEDICINE SPECIAL | LSN MAGAZINE 17 RISE OF THE ROBOTS AUTOMATION IN SURGERY A number of highly innovative projects in the North of Germany aim at taking robot-assisted sur- gery to the next level – based on artificial in- telligence (AI). In Lübeck and Kiel, research- ers, engineers, and clinicians develop and shape the operating theatre of the future. Robotic surgery is already with us. Instruments such as the industry-leading Da Vinci system by US tech giant Intui- tive Surgical, allow surgeons to take control of multiple arms through a hand-operated console, and give them greater dexter- ity and vision when operating in hard-to-reach areas. But the field of robot-assisted surgical technology is in motion: Since the expiry of Intuitive’s patents, new systems from a grow- ing number of manufacturers are now increasingly entering the market. This both enables broader access to this technol- ogy and increases the pressure on manufacturers to innovate. Academic researchers, medical technologists and clinicians in Schleswig-Holstein have stepped in this dynamic field. Sup- ported by the state government and EU funding, they want to significantly improve established robot-assisted surgical tech- nology, developing a new generation of medical robots in an era of digitalization and artificial intelligence. Fully functional operating theater A visit to the Lübeck-based _> Fraunhofer Research Institution for Individualized and Cell-Based Medical Engineering IMTE:

AI IN MEDICINE SPECIAL | LSN MAGAZINE 19 Fraunhofer Institute for Digital Medicine MEVIS and the DFKI Branch Office Lübeck. But what will the patients treated by the sur- gical robots look like? “Our ‘patients’ will be individual anatomical models and phantoms made by 3D printing at the Fraunhofer IMTE,” Rostalski says (also see page 30 in this issue). They will be prepared in a room right next to the operating room. “We will really have a high-tech operating tract here at our insti- tute, matched by a similar setup in the UKSH. This ensures a smooth transition between re- search and clinical practice.” Surgical assistants in Kiel Printed or virtual models in 3D also play an important role in a robot-assisted surgery de- veloped at the Kiel Campus of the UKSH. The project entiteled “Operation room of the Fu- ture” is like the LIROS project financed by the state government via the REACT-EU funding scheme (budget: 3.4 million euros). In Kiel the surgical disciplines are closely networked in minimally invasive and robot-assisted proce- dures under the umbrella of the Kurt Semm Center, which is coordinating the project. _> Kiel University and the companies Vater Solution and _> MiE Medical Imaging Elec- tronics are also involved. The OR of the future focuses on two subproj- ects that are expected to improve surgery in the foreseeable future: one is a so-called AI- based augmented reality solution for even more targeted and gentle tumor surgery. The developed software will help to visualize the conspicuous areas from PET-CT imaging directly in the live surgical image or provide the surgeon with a navigation aid. Augment- ing the image information from computed tomography will not only provide surgeons with enhanced information about the surgical area, but also provide 3D navigation support. This procedure is expected to help identify tumor-positive lymph nodes and other tumor structures more easily during surgery. “The high-precision registration and visual overlay of 3D tumor positions from the CT into the live image supports surgeons during the operation and allows them to identify and remove tumor tissue as quickly and safely as possible. This reduces the duration of the operation and the stress on patients,” explains Reinhard Koch, Prof Philipp Rostalski Director Fraunhofer IMTE Prof Reinhard Koch Dean Faculty of Engineering Kiel University Dr Svenja Ipsen Group leader Robotic intervention at Fraunhofer IMTE Prof Tobias Keck Director Surgical Depart- ment at UKSH Lübeck who is responsible for the first subproject at the Faculty of Engineering of Kiel University. The second subproject coordinated by ro- botics specialist Thomas Meurer deals with the development of an AI-based robotic as- sistance system to optimize workflows and infection control in the OR. Until now, cur- rent surgical robots consist only of a system that is remotely controlled by the surgeon via a console. Operating room assistants support the surgeons, but work directly on the patients by hand with the necessary instruments. The technology currently being developed will enable a two-arm as- sistant robot. For the patients, this should make the operation more precise, infection- proof, faster and gentler. This may shorten the healing time compared to conventional open surgery procedures. Sensors and AI ensure that the two robotic arms do not in- terfere with each other in the process. At the same time, the surgeons’ instruments, such as clamps, must remain in position during all assistance work. A robot with open interfaces Both research consortia in Lübeck and Kiel have decided to cooperate closely and help to make Schleswig-Holstein a key site for research and development in robotic sur- gery. This is exemplified by the use of an upcoming robot platform based on a novel surgical robot called Dexter, which has been developed and commercialized by Swiss company Distalmotion. The system has open interfaces and offers the experts an optimal platform for the development and testing of innovations. “We want to democratize surgical robotics and make them affordable for smaller hospitals,” says Klaus Feldmann, Sales Director Germany. The connection to hospitals in North Germany is so promising that Distalmotion has opened its German office in Hamburg. Philipp Rostalski, who is also a member of the board of Life Science Nord e.V. says: “I’m convinced that the Kiel- Lübeck-Hamburg axis has enormous poten- tial in the field of surgical robotics. There is potential for an ecosystem, which I will also try to strengthen and establish as a focus for- research and development in the Life Science pg Nord cluster.”

NETWORKING | LSN MAGAZINE 21 Medtech Cluster Alliance D-A-CH The Alliance is an association of cluster organizations, networks and initiatives in the medical technology industry. The Alli- ance consists of ten German, five Austrian and one Swiss part- ner. It shapes an innovation and economic region with several thousand medical technology and research partners. The aim of the Alliance is to strengthen the European economic area of the D-A-CH region in terms of international competition. CEBR The Council of European Bio- Regions (CEBR) is a member- driven network of bioscience clusters and regional ecosystems across Europe, representing more than 40 members and hundreds of cluster partners around the world. Thus, CEBR represents and supports a crucial number of SMEs as well as hundreds of universities and research centers. “All our international activities aim at being broadly positioned in the European and global core markets in order to ensure op- timal visibility of our Northern German players. In parallel, we have been building resilient bridges to networks, institu- tions and multipliers worldwide for many years. We are looking forward to expanding existing partnerships and to establish- ing new ones.“ Sarah Niemann, Manager International Affairs, Life Science Nord JAPAN

BUSINESS NORTH | LSN MAGAZINE 23 WE SIMPLIFY SAVING LIVES GUEST ARTICLE Weinmann Emergency Medical Technology, family-owned since 1874, has developed into a world leader in a niche market. The company intends to continue growing and is committed to the North and the City of Hamburg. “We see particular growth potential in telemedicine and the digital networking of products.” vices, with digital deployment documen- tation systems, and with platforms used by the emergency medical services, for example, for device management. Weinmann Emergency is an interna- tionally active, family-owned medical technology company. With transportable solutions for emergency, transport and disaster medicine, it sets standards in sav- ing lives. In close cooperation with profes- sionals from emergency medical services, hospitals and army medical services, the employees in Hamburg develop innovative medical products for ventilation, monitoring/defibrillation and data management. Anyone who saves lives in emergency medi- cine, accompanies intensive care transports or provides assistance in disaster areas knows and trusts Weinmann Emergency. For almost 150 years, Weinmann Emergency has been offering cus- tomers the highest level of reliability, quality and experience. Weinmann Emergency equipment meets the highest demands even under extreme conditions – of course in certified quality. The ventilators and products in the area of monitoring/defi- brillation are just as suitable for emergency use as they are for transporting intensive care patients indoors by sea, land and air or even within hospitals. Because the products are so robust, medical services of armies and civil protection all over the world have been relying on Weinmann Emergency for decades. Many employees at Weinmann Emergency have their own experience from rescue services, disaster control or hospitals, which they use in their daily work. However, the most important impulses for our innovative product developments come from users in the field of emergency medicine. Weinmann Emergen- cy is in close contact with professionals from rescue services, hospitals and armies and speaks their language. Current trends in medical technology do not stop at Weinmann Emergency. The company sees particular growth potential in telemedicine and the digital networking of products. To achieve this, the products must learn to communicate with other de- ANDRÉ SCHULTE However, Weinmann Emergency fo- cuses not only on the products, but also on the appropriate service – no product is sold without a local service partner who can carry out repairs and maintenance. A fleet of mobile service vehicles has been on the road in Germany for 20 years. This makes it possible to help German customers quickly and easily – the rolling workshop is unique. The model has already set a trend beyond Germany’s borders: service vehicles are also in operation in Austria, France and Spain. International service partners are regularly trained and certified. This is a prerequi- site for performing service on the life-saving devices. Weinmann Emergency currently employs just over 300 people from its Hamburg location and intends to continue growing. “We have a great need for experts, especially in the areas of IT, digitalization and software development,” says André Schulte. The move to a new company building in Hamburg Bahrenfeld is scheduled for 2026, a clear commitment to the North and the Hanseatic City of Hamburg. “Our employees are our most valuable asset,” says André Schulte. To keep it that way, events and campaigns are planned with the company’s own WEcom- munity, in which the management is closely involved. “Regular communication and exchange at eye level with our colleagues is very important to us. The ‘We’ in our slogan is just as impor- tant internally as it is in our collaboration with customers and partners. We like to compare this with the work in the rescue service: alone it is difficult to save a person, together it looks quite different.” More information: www.weinmann-emergency.com

BUSINESS NORTH | LSN MAGAZINE 25 Provirex’ current site at the Start- up Labs Bahrenfeld at DESY. The illustration shows how the recombinase Brec1 cuts the HIV provirus from the genome of a T cell. the support of _> Ascenion as a technology transfer partner. Hav- ing the recombinase technology ready for clinical application is perfectly aligned with a biopharma sector that enjoys a booming field of gene and cell therapies. But getting to this point proved to be challenging for the innovators in Hamburg. Initially, some of the scientific community was skeptical about the feasibility of the approach, and investors’ interest in the clinical translation of the Brec1 technology was low. “We were ten years ahead of our time,” says Oliver Ahnfeld, co-founder and CEO of Provirex. Public funding and relentless institutional support from LIV have enabled the researchers to go on and show that the technology is safe and efficient in animals, and to prepare the groundwork for clinical trials in humans. One major milestone was a publication in the acclaimed journal “Nature Biotechnology” in 2016. In this paper, the team demonstrated that Brec1 was capable of specifically re- moving the provirus from the infected cells of most primary HIV-1 isolates. “It means that 94% of HIV patients can be treated with our approach,” says Chemnitz. With these promising results in hand, the LIV team started fundraising and successfully applied, with the UKE, to the Federal Ministry of Education and Research (BMBF) for multi-million euros’ worth of funding. The financial support would be used for a clinical trial named HIVCure. The Hamburg Senate invested another million euros for developing tools needed for the study. HIVCure, a first-in-human phase Ib/IIa clinical trial, is supposed to start recruiting at the UKE at the end of 2023. It aims to remove HIV-1 from infected subjects using gene editing of the pa- tient’s peripheral blood stem cells. “The retransplanted engineered blood stem cells build up an immune system that is now resistant to HIV,” describes Chemnitz. He says Provirex also conducts re- search on the direct delivery of Brec1 by molecular ferries. New investors and new headquarters The start-up was founded in 2019 thanks to seed funding from the City of Hamburg. It received another major boost last year when venture capitalist Bioventure Management and IFB Innovations- starter invested in the enterprise. “This investment will provide financial security for the company over the next four years and help to build a therapy hub in the future Science City Hamburg Bahrenfeld,” says Ahnfeld. In 2024 the new lab, occupying an area of about 500 sqm, is due to be finished. In specially designed cleanrooms, advanced therapy medicinal products (ATMPs) will be produced, while meeting the safety standards for working with hu- man viruses. “In the long term, we will be able to offer any type of personalized medicine for people living with HIV (PLWH) and will be among the first companies worldwide to do so,” says Ahnfeld. dpd/pg More information: www.provirex.de

Evotec’s cell therapy manufacturing site in Modena Automated iPSC-based cell screening plattform The “Lighthouse of iPSCs” is constructed by 2024. BUSINESS NORTH | LSN MAGAZINE 27 CELL-BASED DIABETES CURE REGENERATIVE MEDICINE A beta cell replace- ment therapy jointly developed by Evotec and Sernova is progressing towards the clinic. In type 1 diabetes, insulin producing beta cells, which are normal- ly found in cell clusters (islets) in the pancreas, are destroyed by an errant immune system. A potentially game-changing approach relies on replacing the beta cells in the patients’ body. Pluripotent stem cells allow the creation of these cells in the lab — providing an almost limitless supply of replacement cells. Hamburg-based _> Evotec has built a unique drug discovery and cell therapy plat- form that is based on induced pluripotent stem cells (iPSCs). It in- volves the generation of various iPS cell lines and their controlled differentiation into medically relevant cell types, either for drug screening as human disease models, or for therapeutic use – in- cluding GMP production of clinical-grade material. Evotec’s iPSC- based beta cell replacement program has now made big steps in bringing this innovative treatment to the clinic. In January 2023, Sernova Corp., a regenerative medicine company based in Canada, announced significant progress in its collaboration with Evotec. Over the past years, Evotec has successfully generated an iPSC- derived product consisting of islet-like cell clusters containing a high fraction of beta cells. Under the partnership, Evotec’s iPSC-derived islet-like cell clusters are combined with Sernova’s implantable device called Cell Pouch. It is an implantable and scal- able medical device for long-term survival and function of thera- peutic cells. Evotec and Sernova aim to produce an off-the-shelf, commercially viable, ethically derived cell therapy treatment for insulin-dependent diabetes. The preclinical R&D is so promising that the jointly developed therapy is now progressing towards a first-in-human Phase 1/2 clinical trial for the treatment of patients with type 1 diabetes. The regulatory filing is slated for 2024. Cord Dohrmann, Chief Scientific Officer of Evotec, says: “The combi- nation product is highly differentiated through the quality of the cells and the device but also the scalability of the manufacturing process of the iPSC-derived cells and therefore clearly positioned to become the best-in-class cell therapy in the field.” Meanwhile, Evotec continues to expand its iPSC-based activities. The compa- ny has established a dedicated, high-quality cGMP cell therapy manufacturing site in Modena, Italy. A dedicated and growing process development and scale-up team is located at the Evotec site in Goettingen, Germany. Further, a new 12,000 m2 lab building is being constructed by mid-2024 on the Hamburg-based Manfred Eigen Campus. Dubbed the “Lighthouse of iPSCs”, the new space pg will provide room for up to 250 additional employees. More information: www.evotec.com

SCIENCE & TRANSLATION | LSN MAGAZINE 29 The two pressing questions on efficacy were addressed and answered by a successful joint project within the Hygiene, Infection & Health (HIHeal) network coordinated by the Life Sci- ence Nord cluster. “The beauty of this project is that we used clini- cally relevant strains for the efficacy testing,” says Brill. Medical microbiologist Johannes Knobloch’s team at _> University Medical Center Hamburg-Eppendorf (UKE) pro- vided antibiotic-resistant bacteria strains that caused clinical outbreaks within the last couple of years at the UKE and other German hospi- tals from their collection. This club of notori- ous hospital germs consisted of strains from species such as Staphylococcus aureus, Pseudomo- nas aeruginosa and Klebsiella pneumoniae. Disinfectants doing their job In the study the effectiveness of four surface disinfectants, two agents from disinfection manufacturer _> Bode Chemie and two agents from Dr Weigert were tested in the companies’ own labs and the lab of Dr. Brill + Partner. The results were reassuring: All four surface disinfectant agents perfectly did their job and worked effectively. The researchers also did not observe any shift in the effective concentration of disinfectants. “Another con- clusion is that the reference strains from Euro- pean norms still represent the current clinical antibiotic resistant bacterial community,” says Brill. He is convinced that the validation and generation of solid data can support and up- date international databases of disinfectants and several lists of disinfectants in Germany. The project team is now writing up the results and is to publish the paper in a scientific jour- nal. Just how interesting the data are for the scientific community became clear at the Con- ference of Applied Hygiene, Microbiology and Virology (CAHMV) at the end of November 2022 in Hamburg. “It was obviously the confer- ence talk with the most questions and we had a lively debate,” remembers Brill. His company is the main organizer of the annual conference. One possible next step in the project would be including more disinfectants in the testing. “One could also imagine other testing scenari- os – for example on surfaces instead of in sus- Dr Florian Brill Owner and Managing Director Dr. Brill + Partner Dr Johannes Lenz Manager Microbiology and Hygiene Department at Chemische Fabrik Dr. Weigert Juliane Worm Director Innovation & Technologies at Life Science Nord pension,” Brill explains. He hopes to have more scientific groups and partners join the quest. According to Brill, the project has also exem- plified the strengths and opportunities of the HIHeal network that was established back in 2016. “By connecting different stakeholders from private industry, clinics and academia, we are able to set up joint projects which would otherwise not have been started,” states Brill. His company in particular acted as a platform and intermediary between the more scientifically oriented experts in the hospitals and universities on the one hand and the private companies on the other. “Many of the industrial players are also competitors in certain areas. Normally they would not intend on joining such a project. However, under the umbrella of HIHeal, it’s easier to collaborate and bring relevant experts together,” he says. In this way, the network actively helps to establish sustainable connections across the infectious disease and infection prevention ecosystem in the North. The disinfectants efficacy testing project also presented some confidentiality issues that had to be solved. “Everybody was open to solving these chal- lenges because we were all interested in the outcome and in the science behind it,” explains Brill. The collaborative spirit was also what Johannes Lenz from Dr. Weigert particularly liked about this HIHeal project: “The cooperation between disinfectant man- ufacturers, testing laboratories and users is a very good example of how practical solutions can be developed hand in hand.” Networking perspectives Juliane Worm, Director Innovation & Tech- nologies at Life Science Nord, who has been responsible for HIHeal, is not only happy with the outcome of the respective project, but also thrilled with the fruitful network- ing that goes on. “The HIHeal activities will receive one more year of funding from the Hamburg Department of Economics, Trans- port and Innovation (BWI) in 2023,” Worm says. “This is great news for the many areas pg/mm dealt with by this project.” More information: www.lifesciencenord.de

SCIENCE & TRANSLATION | LSN MAGAZINE 31 3D PRINTING MEETS MEDICINE PRECISION MEDICINE 3D printing is profoundly shaping the future of medicine and healthcare. Researchers in the North combine artificial intelligence with state-of-the-art additive manufacturing technologies and develop bioresorbable mate- rials and innovative bioprinting techniques to take precision medicine to the next level. In dentistry, the 3D printing revo- lution is already routine: patients benefit from individualized im- plants produced by additive man- ufacturing (AM) – or 3D print- ing – technologies. Many dental practices use their own 3D print- ers to manufacture dental crowns or bite splints. In the future, this technology will gradually move into clinics and enable the pro- duction of precise anatomical models and individualized surgi- cal implants. “Nowadays, patients are well informed and demand the highest quality of care. They don’t want off-the-shelf products, which don’t fit their needs. I think that in the future, patients are no longer going to adapt to their treatment, the treatment is going to adapt to them,” predicts Thomas Friedrich, Head of Additive Manufac- turing at the _> Fraunhofer Institution for Individualized and Cell-Based Medical Engineering (IMTE) in Lübeck. Through a combination of their long-standing expertise in cell biology and AM, since 2020 researchers at the new institute have been working towards shaping the future of precision medicine by advancing medical products such as surgical implants. One area of focus that bridges these two competencies is research at the interface between implants and the body. “We want to understand how the surface of an implant, and its structure in particular, influence the ingrowth behavior of cells or the risk of rejection and infection. This research will help to improve the “Patients are no longer going to adapt to their treatment, but the treatment is going to adapt to them.” DR THOMAS FRIEDRICH HEAD OF ADDITIVE MANUFACTURING AT FRAUNHOFER IMTE longevity of implants and reduce the need for a second operation,” summarizes Friedrich. AM tech- nologies developed at Fraunhofer IMTE allow the surface of a ma- terial to be shaped on nanometer and micrometer scale, which is ideal when it comes to studying the growth of cells or organoids. Fraunhofer IMTE and its partner, the _> University of Lübeck, ac- commodate more than twenty 3D printers, which mainly use poly- mers – or plastic – as a starting ma- terial. Some of these printers pro- duce anatomical models for training medical professionals. These allow surgeons to practice challenging interventions such as the treatment of aneurysms or stroke in realistic environments, before moving on to patients. Additional printers using titanium feedstock will soon be available to enhance the study of the surface properties of titanium implants. But research- ers at IMTE also look further into the future when it comes to the most suitable implant materials: “I believe that one day, no patient will want to have a foreign body implanted, if an organic, living implant that integrates seamlessly into the body were available as an alternative,” says Friedrich. Bioprinting is a budding technology that will take patient-spe- cific implants to a completely new level. By using a patient’s living cells to manufacture 3D implants such as tissues or even organs, the risk of rejection can be minimized and the long wait

SCIENCE & TRANSLATION | LSN MAGAZINE 33 33 manufactured by external service providers who must ship the product to the clinic. By using AI, optimizing manufacturing, and combining all these processes under one roof, we have de- creased production time from nine to three days,” summarizes Gromzig. So far, the collaboration team has focused on the pro- duction of orbital implants. These wafer-thin titanium plates are used to treat injuries of the eye socket. In the future, many other bone injuries could be treated using the AI-based work- flow developed at Fraunhofer IAPT, and the team has shown that it can be integrated in hospitals or enterprises. “We have demonstrated that the implants are safe and produced in line with the current Medical Device Regulation (MDR). However, legal barriers remain, as it is not yet certain who is liable should AI make a mistake,” says Gromzig. Two AI-algorithms are at the heart of the DigiMed workflow: one analyzing CT scans of a patient’s anatomy and the other designing the virtual implant. “This technology could cause a paradigm shift in the production of personalized implants, with great added value for patients, whose time in hospital will be shortened significantly. There- fore, our next goal is to bring the workflow into the clinic,” adds Gromzig. Magnesium – biomaterial of the future Further improvements for patients with bone injuries can be expected of research into highly innovative, bioresorb- able implant materials like magnesium. Down the corridor at Fraunhofer IAPT, Kevin Janzen is working on a novel 3D printing process using magnesium alloys as a starting mate- rial. “Unlike titanium, magnesium has the advantage that it decomposes inside the body. Therefore, bone implants don’t have to be removed in a second operation,” explains Janzen. For project BioMag3D, the engineers optimize the process of sinter-based Additive Manufacturing of magnesium, in which printed parts undergo a heat treatment. “One advantage of this technology is that it allows us to build hollow structures into the implant. These help us to control the rate of degradation and thereby aid the healing process,” adds the mechanical engineer. But using magnesium also has its downsides. Firstly, its chemical properties complicate 3D printing and secondly, hydrogen gas builds up as the implants decompose. To tackle these issues, the Fraunhofer researchers are closely collaborating with engineers at the _> Helmholtz- Zentrum hereon in Geesthacht to optimize the properties of the feedstock. Within the next three years, the team will test the properties of their implants in petri dishes, before in vivo experiments take place. Janzen estimates that it will take at least ten years until the first 3D printed magnesium implants produced with this method enter the clinic: “Our technology is still very new, but we are in regular contact with medical staff at the UKE and the BG Hospital Hamburg to develop implants for the treatment of complicated bone fractures of the arm,” dpd explains Janzen. Magnesium alloy as starting material for 3D printing. Fraunhofer researcher Phillip Gromzig A microrobot swims in a model of an artery.

LIQUID BIOPSY HOTSPOT The Life Science Nord Cluster, and here in particular the Hamburg region, represents a highly active region in the area of liquid biopsy approaches for cancer diagnostics. A recent publica- tion of the biotechnology sector as- sociation BIO Deutschland identifies the folllowing players with important research and development activities in the field:  Asklepios Tumorzentrum Hamburg  Fraunhofer IAP/CAN  Indivumed  Medical Center Hamburg-Eppen- dorf (UKE) More information: www.biodeutschland.org SCIENCE & TRANSLATION | LSN MAGAZINE 35 stream. The Fraunhofer researchers use magnetic nanoparticles that help to detect and target the tumor cells. They can then dock onto the cancerous cells or their cell products and be concentrated in a magnetic field, thus allowing the tumor cells to be closely ex- amined. The second step of the procedure consists of decorating those cells with a wide range of fluorescent particles that are also specialized to target specific cell types. The fluorescence and its pat- terns can then be measured and analyzed to detect what type and degree of cancer the patient has. Liquid biopsy has been studied for years now and many labs are making progress in the cancer field. However, the FDA-approved method currently on the market is using only a limited amount of one or two fluorophore markers. “What sets our project apart is that we are testing a wide range of different kinds of fluorescent particles. This allows for multiplex- ing, meaning that different fluorescence signals can be detected simultaneously,” says Feliu Torres. Nanoparticles as signal enhancer She points out that the use of nanoparticles is especially valuable for signal enhancement. The team is designing a variety of distinct particles with the capability to bind with specific types of tumor. This will improve the sensitivity, specificity, and speed of the de- tection process, as well as making it more cost-effective. Although focusing on the detection of breast and prostate cancer, the proj- ect is aiming to expand their particles’ abilities to detecting any cancer that releases biomarkers into the blood stream. But cancer doesn’t have to be the limit, says Feliu Torres. “Our particles could be widely used in medicine, as a diagnostic system, but also as a drug delivery agent,” the bionanotechnologist says. She hopes to find more collaboration partners from the industry. “Our particles can be of service in many more nanomedical applications.” mm DR NEUS FELIU TORRES leads a working group at the Fraunhofer Center for Applied Nanotechnol- ogy CAN in Hamburg. Born in Spain, she received her doctorate from the Karolinska Institute in Stockholm.

PROFILE | LSN MAGAZIN 37 PROF CHRISTIAN GERLOFF In January 2023, the brain imaging special- ist started his job as Medical Director of the University Medical Cen- ter Hamburg-Eppendorf (UKE) THE BRAIN- STORMER

BOOTCAMP | LSN MAGAZINE 39 STARTING UP IN THE NORTH INCUBATORS, ADVICE & FINANCING FOR LIFE SCIENCE COMPANIES Flensburg → IHK → GATEWAY 49 → Technologiezentrum WiREG Kiel → IHK → WTSH → StartUp Sh → KI-Transfer-Hub SH €€€ → IB.SH → Baltic Business Angels → MBG SH → Mentoren SH → Kieler Innovations- und Technologiezentrum KITZ Itzehoe → Innovationszentrum Itzehoe IZET Hamburg → beyourpilot → Tutech → AI.Startup.Hub → Innovations Kontakt Stelle → Startup Port → GWHH → HK Hamburg → Artificial Intelligence Center ARIC → Health Innovation Port → Startup Dock → DESY Start-up Office → Start-up Labs Bahrenfeld → Hamburg Invest → Hammerbrooklyn €€€ → IFB → Hamburger Existenzgründungs initiative → Hamburg Investors Network Lübeck → IHK → GATEWAY49 → Hanse Innovation Campus Lübeck → Technikzentrum Lübeck

CAREER | LSN MAGAZINE 41 41 ABOUT ALLERGOPHARMA 350 employees are working for the company 400+ authorized prep- arations for allergen immunotherapy PHARMA INNOVATION MADE IN GERMANY GUEST ARTICLE Since its foundation in 1969 Allergopharma has specialized in the develop- ment, production and commercialization of medical drugs for the diagnosis and treatment of allergic diseases. Specific allergy immunotherapy is aiming to reduce allergic symptoms like allergic rhinitis and conjunctivitis and prevent and treat allergic asthma. Allergopharma is a global leader in the field of allergy therapeutics. More than 330 scientists, tech- nicians and marketing experts at the headquarters in Reinbek near Hamburg are constantly working on improving life and health of allergic patients. Allergopharma’s products are ap- proved and available in several European countries and in Asia. Committed to people: At Allergopharma people are the focus of everything we do. “Allergies do significantly reduce quality of life of patients. This is why we are striving to make high quality sterile drugs available to improve patients’ health,” says Dr Christoph Willers, CEO of Allergopharma. Professional Opportunity: We offer experienced profession- als and outstanding top talents various opportunities to proof their excellence and achieve targets beyond the regular per- spective. By offering an exciting and innovative work environ- ment and best-in-class training programs Allergopharma will kick-start your career in the pharmaceutical industry. Benefits: At our modern global company headquarters and a newly build state-of-the-art manufacturing site in Reinbek near Hamburg, you can expect inspiring colleagues, challeng- ing tasks, flat hierarchies and numerous attractive benefits. Your career with us: If you are an outstanding personality, top-class professional and always curious for the next target to achieve, we want you to shape the future of Allergopharma. Ensure that you can get the optimal platform to booster your career and go beyond conventional thinking at Allergopharma. If you are looking for new opportunities to express your pas- sion in one of our fields and would like to work in a modern environment, take a look at our current vacancies at our web- site and apply directly online or visit us on our social media channels on LinkedIn or XING or send us a direct application. More information: www.allergopharma.de/karriere

LIFE SCIENCE NORD CLUSTER | LSN MAGAZINE 43 CLUSTER MEMBERS _> Please find more cluster members at: www.lifesciencenord.de